National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Dictionary of Cancer Terms

Page Options
Print This Page  Print This Page
More NCI Dictionaries
NCI Drug Dictionary

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Questions about cancer?

1-800-4-CANCER
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Kepivance (KEH-puh-vants)

  A form of keratinocyte growth factor (KGF) that is made in the laboratory. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract. Kepivance is used to prevent and treat oral mucositis (mouth sores) caused by high-dose chemotherapy and radiation therapy in leukemia and lymphoma. It is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer. Kepivance is a type of recombinant human keratinocyte growth factor. Also called palifermin.

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov